| # | Drug | Count |
|---|---|---|
| 0 | OCRELIZUMAB | 41 |
| 1 | RITUXIMAB | 18 |
| 2 | AGALSIDASE BETA | 17 |
| 3 | MYCOPHENOLATE MOFETIL | 14 |
| 4 | PREDNISONE | 14 |
| 5 | ADALIMUMAB | 10 |
| 6 | CYCLOSPORINE | 9 |
| 7 | DILUENT | 9 |
| 8 | IBRUTINIB | 9 |
| 9 | MONTELUKAST SODIUM | 7 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DILUENT | 9 | 0.0087 |
| 1 | TEA TREE OIL | 1 | 0.0053 |
| 2 | AVALGLUCOSIDASE ALFA-NGPT | 2 | 0.0020 |
| 3 | AGALSIDASE BETA | 17 | 0.0018 |
| 4 | TALIGLUCERASE ALFA | 1 | 0.0017 |
| 5 | ALGLUCOSIDASE ALFA | 3 | 0.0012 |
| 6 | OCRELIZUMAB | 41 | 0.0007 |
| 7 | ACALABRUTINIB | 3 | 0.0002 |
| 8 | RITUXIMAB-ABBS | 1 | 0.0002 |
| 9 | FLECAINIDE ACETATE | 1 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] | 17 | 0.0017 |
| 1 | Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] | 5 | 0.0015 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 53 | 0.0002 |
| 3 | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] | 1 | 0.0001 |
| 4 | Cannabinoid [EPC] | 1 | 0.0001 |
| 5 | Antimetabolite Immunosuppressant [EPC] | 2 | 0.0001 |
| 6 | Calcineurin Inhibitor Immunosuppressant [EPC] | 10 | 0.0001 |
| 7 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 1 | 0.0001 |
| 8 | Alkaloid [EPC] | 2 | 0.0001 |
| 9 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 1 | 0.0001 |